Last reviewed · How we verify
NCT03272802
Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)
Phase 2, PHASE3 trial testing Edaravone in Neuromuscular Diseases in 20 participants. Status unknown.
16 March 2019
Quick facts
| Lead sponsor | Isfahan University of Medical Sciences |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 16 March 2017 |
| Primary completion | 16 March 2019 |
| Estimated completion | 16 September 2019 |
| Sites | 1 location across Iran |
Drugs / interventions tested
Conditions studied
- Neuromuscular Diseases — all drugs for Neuromuscular Diseases →
Sponsor
Isfahan University of Medical Sciences
Who can join
Adults 18 to 75, any sex, with Neuromuscular Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that causes the death of 30,000 affected individual every year. Complex nature and unknown pathogenesis of this disease are 2 major reasons for failure of therapeutic interventions. Edaravone is a free radical scavenger that slows down functional decline and prevents from disease progression in ALS patients. FDA newly approved this drug in these patients (2017/5/5). In this study, investigators aimed to assess the treatment effect of this newly approved drug in patients with ALS in a representative Iranian population.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis.
Cho H, Shukla S. · · 2020 · cited 79× · PMID 33396271 · DOI 10.3390/ph14010029 -
Glial Cells-The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment.
Filipi T, Hermanova Z, Tureckova J, Vanatko O, et al · · 2020 · cited 52× · PMID 31963681 · DOI 10.3390/jcm9010261 -
Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders.
Shah S, Dooms MM, Amaral-Garcia S, Igoillo-Esteve M. · · 2021 · cited 32× · PMID 34992533 · DOI 10.3389/fphar.2021.768023 -
Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis.
Nourelden AZ, Kamal I, Hagrass AI, Tawfik AG, et al · · 2023 · cited 15× · PMID 37249667 · DOI 10.1007/s10072-023-06869-8 -
Safety and efficacy of edaravone in well-defined Iranian patients with amyotrophic lateral sclerosis: A parallel-group single-blind trial.
Eishi-Oskouei A, Basiri K. · · 2021 · cited 5× · PMID 38011420 · DOI 10.18502/cjn.v20i1.6373 -
Neuro-Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets.
Guo X, Liu H, Song YJ, Wang JH, et al · · 2026 · cited 2× · PMID 41583906 · DOI 10.1002/mco2.70497 -
p53: from understanding its structure to advances in therapeutic targeting.
Wang W, Liu X, Liu H, Abolhassani H, et al · · 2026 · PMID 41942427 · DOI 10.1038/s41392-025-02549-5
Verify or expand the search:
- PubMed search for NCT03272802
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Edaravone
Trials testing the same drug.
- NCT05540262 — Edaravone in the Treatment of Optic Neuritis · NA · recruiting
- NCT04391361 — The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS · Phase 2 · unknown
Other recruiting trials for Neuromuscular Diseases
Currently open trials in the same condition.
- NCT07287189 — Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients · Phase 2 · recruiting
- NCT06367686 — Detecting Systemic Carbon Dioxide Levels With a Novel Biosensor · recruiting
- NCT06119087 — Mechanical Insufflation in the Philadelphia Amyotrophic Lateral Sclerosis Cohort (MI-PALS) Study · NA · active not recruiting
- NCT06151600 — A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J · recruiting
- NCT06553976 — Spastic Paraplegia - Centers of Excellence Research Network · recruiting
Other Isfahan University of Medical Sciences trials
Trials by the same sponsor.
- NCT06991933 — Construction and Educational Impact of Plastination Models of the Limbic System, Basal Nuclei, Cerebellum, and Human Spi · NA · not yet recruiting
- NCT07031960 — 3D Eye Movement Simulator for Medical Education · NA · not yet recruiting
- NCT07195370 — Testing YAG Laser Iridotomy for Primary Angle-Closure Glaucoma · NA · active not recruiting
- NCT06642363 — The Effectiveness of Astaxanthin Supplementation on the Clinical Symptoms and Cardio-metabolic Profile in Women with Pol · Phase 1 · recruiting
- NCT06379659 — Effectiveness of Intrauterine Growth Hormone Administration as an add-on Therapy to Conventional Hormone Therapy Compare · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03272802 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Isfahan University of Medical Sciences
- Last refreshed: 27 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03272802.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing